Head-To-Head Comparison: Vyome (NASDAQ:HIND) versus ReShape Lifesciences (OTCMKTS:RSLSD)

Vyome (NASDAQ:HIND) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares Vyome and ReShape Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-69.71%	-216.95%	-69.42%
ReShape Lifesciences	-668.58%	-163.22%	-52.10%

Analyst Ratings

This is a breakdown of recent ratings for Vyome and ReShape Lifesciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	0	0	2	0	3.00
ReShape Lifesciences	0	0	0	0	0.00

Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 173.22%. Given Vyome’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vyome is more favorable than ReShape Lifesciences.

Risk and Volatility

Vyome has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vyome and ReShape Lifesciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$8.01 million	2.51	-$7.13 million	($433.08)	-0.01
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A

Vyome has higher revenue and earnings than ReShape Lifesciences.

Institutional & Insider Ownership

22.1% of Vyome shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vyome beats ReShape Lifesciences on 8 of the 11 factors compared between the two stocks.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.